Statins and ALS: The possible role of impaired LXR signaling

Medical Science Monitor

Volumn 16, Issue 3, 2010, Pages

  Bełtowski, Jerzy ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Amyotrophic lateral sclerosis; Liver X receptor; Oxysterols; Phytosterols; Statins 3 hydroxy 3 methylglutaryl coenzyme A reductase

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN; ATORVASTATIN; BRASICASTEROL; CAMPESTEROL; COMPACTIN; COPPER ZINC SUPEROXIDE DISMUTASE; ERGOSTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; OXYSTEROL; PHYTOSTEROL; PITAVASTATIN; PRAVASTATIN; RETINOID X RECEPTOR ALPHA; ROSUVASTATIN; SIMVASTATIN; STEROL; STIGMASTEROL; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DATA BASE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FAMILIAL DISEASE; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HEALTH CARE ORGANIZATION; HUMAN; LIVER TOXICITY; MYOPATHY; NONHUMAN; PATHOGENESIS; PREVALENCE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; WORLD HEALTH ORGANIZATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; MODELS, BIOLOGICAL; ORPHAN NUCLEAR RECEPTORS; PHYTOSTEROLS; SIGNAL TRANSDUCTION;

EID: 77649260798     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Shepherd J, Cobbe SM, Ford I et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333: 1301-7
2. Downs JR, Clearfield M, Weis S et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998; 279: 1615-22
3. Bersano A, Ballabio E, Lanfranconi S et al: Statins and stroke. Curr Med Chem, 2008; 15: 2380-92
4. Simko F: Statins: a perspective for left ventricular hypertrophy treatment. Eur J Clin Invest, 2007; 37: 681-91
5. Reiss AB, Wirkowski E: Role of HMG-CoA reductase inhibitors in neurological disorders: progress to date. Drugs, 2007; 67: 2111-20
6. Niedzielska I, Janic T, Cierpka S, Świȩtochowska E: The effect of chronic periodontitis on the development of atherosclerosis: review of the literature. Med Sci Monit, 2008; 14(7): RA103-6
7. Kashani A, Phillips CO, Foody JM et al: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation, 2006; 114: 2788-97
8. Kiortsis DN, Filippatos TD, Mikhailidis DP et al: Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis, 2007; 195: 7-16
9. Cozzolino M, Ferri A, Carrì MT: Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. Antioxid Redox Signal, 2008; 10: 405-43
10. Rothstein JD: Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol, 2009; 65(Suppl.1): S3-9
11. Edwards IR, Star K, Kiuru A: Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf, 2007; 30: 515-25
12. Colman E, Szarfman A, Wyeth J et al: An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf, 2008; 17: 1068-76
13. Drory VE, Bronipolsky T, Artamonov I, Nefussy B: Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis. J Neurol Sci, 2008; 273: 81-83
14. Zinman L, Sadeghi R, Gawel M et al: Are statin medications safe in patients with ALS? Amyotroph Lateral Scler, 2008; 9: 223-28
15. Golomb BA, Kwon EK, Koperski S, Evans MA: Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: An analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf, 2009; 32: 649-61
16. Bełtowski J: Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Cardiovasc Ther, 2008; 26: 297-316
17. Joseph SB, McKilligin E, Pei L et al: Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA, 2002; 99: 7604-9
18. Terasaka N, Hiroshima A, Koieyama T et al: T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett, 2003; 536: 6-11
19. Gabbi C, Warner M, Gustafsson JA: Minireview: liver X receptor beta: emerging roles in physiology and diseases. Mol Endocrinol, 2009; 23: 129-36
20. Andersson S, Gustafsson N, Warner M, Gustafsson JA: Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc Natl Acad Sci USA, 2005; 102: 3857-62
21. Cutler RG, Pedersen WA, Camandola S et al: Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol, 2002; 52: 448-57
22. Janowski BA, Willy PJ, Devi TR et al: An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature, 1996; 383: 728-31
23. Chen W, Chen G, Head DL et al: Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab, 2007; 5: 73-79
24. Lutjohann D, Papassotiropoulos A, Bjorkhem I et al: Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res, 2000; 41: 195-98
25. Locatelli S, Lutjohann D, Schmidt HH et al: Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol, 2002; 59: 213-16
26. Fassbender K, Stroick M, Bertsch T et al: Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology, 2002; 59: 1257-58
27. Vega GL, Weiner MF, Lipton AM et al: Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol, 2003; 60: 510-15
28. Thelen KM, Lutjohann D, Vesalainen R et al: Effect of pravastatin on plasma sterols and oxysterols in men. Eur J Clin Pharmacol, 2006; 62: 9-14
29. Thelen KM, Laaksonen R, Paiva H et al: High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol, 2006; 46: 812-16
30. Wong J, Quinn CM, Brown AJ: Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol, 2004; 24: 2365-71
31. Wong J, Quinn CM, Brown AJ: Synthesis of the oxysterol, 24(S),25-epoxycholesterol, parallels cholesterol production and may protect against cellular accumulation of newly-synthesized cholesterol. Lipids Health Dis, 2007; 6: 10
32. Forman BM, Ruan B, Chen J et al: The orphan nuclear receptor LXRβ is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci USA, 1997; 94: 10588-93
33. DeBose-Boyd RA, Ou J, Goldstein JL, Brown MS: Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. Proc Natl Acad Sci USA, 2001; 98: 1477-82
34. Ando H, Tsuruoka S, Yamamoto H et al: Effects of pravastatin on the expression of ATP-binding cassette transporter A1. J Pharmacol Exp Ther, 2004; 311: 420-25
35. Sone H, Shimano H, Shu M et al: Statins downregulate ATP-bindingcassette transporter A1 gene expression in macrophages. Biochem Biophys Res Commun, 2004; 316: 790-94
36. Llaverias G, Rebollo A, Pou J et al: Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol, 2006; 71: 605-14
37. Qiu G, Hill JS: Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway. J Cardiovasc Pharmacol, 2008; 51: 388-95
38. Zanotti I, Poti F, Favari E et al: Pitavastatin effect on ATP binding cassette A1-mediated lipid efflux from macrophages: evidence for liver X receptor (LXR)-dependent and LXR-independent mechanisms of activation by cAMP. J Pharmacol Exp Ther, 2006; 317: 395-401
39. Jiang YJ, Lu B, Kim P et al: Regulation of ABCA1 expression in human keratinocytes and murine epidermis. J Lipid Res, 2006; 47: 2248-58
40. Bensinger SJ, Bradley MN, Joseph SB et al: LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell, 2008; 134: 97-111
41. Gouedard C, Koum-Besson N, Barouki R, Morel Y: Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol, 2003; 63: 945-56
42. Madsen L, Petersen RK, Steffensen KR et al: Activation of liver X receptors prevents statin-induced death of 3T3-L1 preadipocytes. J Biol Chem, 2008; 283: 22723-36
43. Qiu G, Hill JS: Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages. J Lipid Res, 2007; 48: 2112-22
44. Patel MD, Thompson PD: Phytosterols and vascular disease. Atherosclerosis, 2006; 186: 12-19
45. Nguyen L, Salen G, Shefer S et al: Unexpected failure of bile acid malabsorption to stimulate cholesterol synthesis in sitosterolemia with xanthomatosis. Comparison with lovastatin. Arteriosclerosis, 1990; 10: 289-97
46. Nguyen LB, Shefer S, Salen G et al: Regulation of 3-hydroxy-3- methylglutaryl-coenzyme A reductase activity in the rat ileum: effects of bile acids and lovastatin. Metabolism, 1994; 43: 1446-50
47. Miettinen TA, Gylling H, Lindbohm N et al, Finnish Treat-to-Target Study Investigators: Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med, 2003; 141: 131-37
48. Miettinen TA, Gylling H: Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur J Clin Invest, 2003; 33: 976-82
49. Wilson JM, Khabazian I, Wong MC et al: Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour. Neuromolecular Med, 2002; 1: 207-21
50. Tabata RC, Wilson JM, Ly P et al: Chronic exposure to dietary sterol glucosides is neurotoxic to motor neurons and induces an ALS-PDC phenotype. Neuromolecular Med, 2008; 10: 24-39
51. Kim HJ, Fan X, Gabbi C et al: Liver X receptor beta (LXRβ): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia. Proc Natl Acad Sci USA, 2008; 105: 2094-99
52. Holmøy T: T cells in amyotrophic lateral sclerosis. Eur J Neurol, 2008; 15: 360-66
53. Noël B: Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol, 2007; 21: 17-24
54. Wong J, Quinn CM, Gelissen IC, Brown AJ: Endogenous 24(S),25- epoxycholesterol fine-tunes acute control of cellular cholesterol homeostasis. J Biol Chem, 2008; 283: 700-7